Results 291 to 300 of about 1,940,722 (375)
Some of the next articles are maybe not open access.

Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals.

Bioconjugate chemistry, 2017
The development of (radio)pharmaceuticals with favorable pharmacokinetic profiles is crucial for allowing the optimization of the imaging or therapeutic potential and the minimization of undesired side effects.
C. Müller   +5 more
semanticscholar   +1 more source

The binding of chlorothiazide to plasma proteins

Biochimica et Biophysica Acta (BBA) - Protein Structure, 1971
Abstract Association constants and values for the enthalpy and entropy of binding of chlorothiazide to human serum albumin have been determined by a variety of methods. The influence of chlorothiazide binding on the plasma levels of the hypotensive drug pempidine has been considered.
A. Rosen, A. Breckenridge
openaire   +3 more sources

Plasma Protein Binding Structure-Activity Relationships Related to the N-Terminus of Daptomycin.

ACS Infectious Diseases, 2017
Daptomycin is a lipopeptide antibiotic that is highly bound to plasma proteins. To date, the plasma components and structure-activity relationships responsible for the plasma protein binding profile of daptomycin remain uncharacterized.
E. Schneider   +10 more
semanticscholar   +1 more source

THE BINDING OF URATE BY PLASMA PROTEINS

Australian Journal of Experimental Biology and Medical Science, 1979
SummaryProtein binding of urate may have some pertinence to the pathogenesis of goat. However, binding studies have been hampered by problems with in vitro methodology and by the problem of relating the results of in vitro studies to the physiological situation.In the present study urate binding was determined by an ultrafiltration procedure.
John Rl Masarei, Joseph Bertolini
openaire   +3 more sources

Plasma Protein Binding of Challenging Compounds.

Journal of Pharmacy and Science, 2015
Accurately determining fraction unbound (fu ) with currently available methods has been challenging for certain compounds. Inaccurate fu values can lead to the misinterpretation of important attributes of a drug candidate.
K. Riccardi   +7 more
semanticscholar   +1 more source

Binding of flavonoids to plasma proteins

2001
International ...
Dangles, O.   +4 more
openaire   +4 more sources

Plasma Protein Binding of Bepridil

The Journal of Clinical Pharmacology, 1985
The binding of the calcium‐channel blocking agent, bepridil HCl (Vascor), to plasma proteins was investigated using radiolabeled bepridil and equilibrium dialysis. Greater than 99.7% of added bepridil‐14C was found to freshly collected human plasma. The binding was characterized by a saturable high‐affinity site (KD = 32 ng/mL = 87 nM) on alpha1‐acid ...
Barry H. Dvorchik   +3 more
openaire   +3 more sources

The binding of ibuprofen to plasma proteins

European Journal of Clinical Pharmacology, 1983
The binding of ibuprofen to human serum albumin, normal plasma and plasma obtained from rheumatoid arthritic patients was studied using the method of ultracentrifugation. It was found that ibuprofen is more strongly bound to normal plasma than to human serum albumin although this result is probably explained by fatty acid contamination of the human ...
M Siddiqui, D M Grennan, Leon Aarons
openaire   +3 more sources

Pharmacokinetics, Biodistribution, Excretion and Plasma Protein Binding Studies of Acteoside in Rats

Drug Research, 2015
Acteoside is a representative phenylethanoid glycoside, exhibiting great potency in neurodegenerative diseases treatment, such as Alzheimer’s disease. This study was aimed to explore the pharmacokinetic characteristics, tissue distribution, excretion and
Yanli Wen   +9 more
semanticscholar   +1 more source

Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European Bioanalysis Forum.

Bioanalysis, 2014
Plasma protein binding (PPB) is an important parameter for a drug's efficacy and safety that needs to be investigated during each drug-development program.
B. Buscher   +9 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy